Cystatin C is differentially involved in multiple system atrophy phenotypes

Neuropathology and Applied Neurobiology

Volumn 41, Issue 4, 2015, Pages 507-519

  Urbizu, Aintzane ^a   Canet Pons, Julia ^a   Munoz Marmol, Ana M ^a   Aldecoa, Iban ^b   Lopez, Maria T ^a   Compta, Yaroslau ^b   Alvarez, Ramiro ^a   Ispierto, Lourdes ^a   Tolosa, Eduardo ^b   Ariza, Aurelio ^a,c   Beyer, Katrin ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cathepsin B expression; Cathepsin D expression; Cathepsin L1 expression; Cystatin C expression; MSA phenotype; Multiple system atrophy (MSA)

Indexed keywords

CATHEPSIN B; CATHEPSIN D; CATHEPSIN L1; CYSTATIN C; MESSENGER RNA; UNCLASSIFIED DRUG; CTSB PROTEIN, HUMAN; CTSD PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CAUDATE NUCLEUS; CEREBELLUM ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTATIN C GENE; DENTATE NUCLEUS; FEMALE; GENE; GENE OVEREXPRESSION; GLIA; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NERVE DEGENERATION; PARANEOPLASTIC NEUROPATHY; PARKINSONISM; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PURKINJE CELL; SHY DRAGER SYNDROME; SPINOCEREBELLAR DEGENERATION; VERY ELDERLY; CEREBELLUM; CEREBELLUM DISEASE; GENETICS; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; CATHEPSIN B; CATHEPSIN D; CAUDATE NUCLEUS; CEREBELLAR DISEASES; CEREBELLUM; CYSTATIN C; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; PHENOTYPE; RNA, MESSENGER;

EID: 84929253547     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12134     Document Type: Article

References (48)

1. Schrag A, Wenning GK, Quinn N, Ben Shlomo Y. Survival in multiple system atrophy. Mov Disord 2008; 23: 294-296
2. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676
3. Wenning GK, Stefanova N. Recent developments in multiple system atrophy. J Neurol 2009; 256: 1791-1808
4. Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-1178
5. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998; 251: 205-208
6. Wenning GK, Wagner S, Daniel S, Quinn NP. Multiple system atrophy: sporadic or familial? Lancet 1993; 342: 681
7. Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, Sasaki H. Heredity in multiple system atrophy. J Neurol Sci 2006; 240: 107-110
8. Wullner U, Abele M, Schmitz-Huebsch T, Wilhelm K, Benecke R, Deuschl G, Klockgether T. Probable multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 2004; 75: 924-925
9. Hara K, Momose Y, Tokiguchi S, Shimohata M, Terajima K, Onodera O, Kakita A, Yamada M, Takahashi H, Hirasawa M, Mizuno Y, Ogata K, Goto J, Kanazawa I, Nishizawa M, Tsuji S. Multiplex families with multiple system atrophy. Arch Neurol 2007; 64: 545-551
10. Lincoln SJ, Ross OA, Milkovic NM, Dickson DW, Rajput A, Robinson CA, Papapetropoulos S, Mash DC, Farrer MJ. Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. Parkinsonism Relat Disord 2007; 13: 340-342
11. Combarros O, Infante J, Llorca J, Berciano J. Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord 2003; 18: 1385-1386
12. Furiya Y, Hirano M, Kurumatani N, Nakamuro T, Matsumura R, Futamura N, Ueno S. Alpha-1-antichymotrypsin gene polymorphism and susceptibility to multiple system atrophy (MSA). Brain Res Mol Brain Res 2005; 138: 178-181
13. Infante J, Llorca J, Berciano J, Combarros O. Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factoralpha gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci 2005; 228: 11-13
14. Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, Sasaki H. Associations between multiple system atrophy and polymorphisms of SLC1A4, SQSTM1, and EIF4EBP1 genes. Mov Disord 2008; 23: 1161-1167
15. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 2000; 1477: 98-111
16. Nagai A, Terashima M, Sheikh AM, Notsu Y, Shimode K, Yamaguchi S, Kobayashi S, Kim SU, Masuda J. Involvement of cystatin C in pathophysiology of CNS diseases. Front Biosci 2008; 13: 3470-3479
17. Kaur G, Mohan P, Pawlik M, DeRosa S, Fajiculay J, Che S, Grubb A, Ginsberg SD, Nixon RA, Levy E. Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy. Am J Pathol 2010; 177: 2256-2267
18. Tizon B, Sahoo S, Yu H, Gauthier S, Kumar AR, Mohan P, Figliola M, Pawlik M, Grubb A, Uchiyama Y, Bandyopadhyay U, Cuervo AM, Nixon RA, Levy E. Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS ONE 2010; 5: e9819
19. Pirttilä TJ, Lukasiuk K, Håkansson K, Grubb A, Abrahamson M, Pitkänen A. Cystatin C modulates neurodegeneration and neurogenesis following status epilepticus in mouse. Neurobiol Dis 2005; 20: 241-253
20. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon RA, Frangione B, Levy E. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 2004; 25: 1033-1043
21. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A. Cystatin C reduces the in vitro formation of soluble Aβ1-42 oligomers and protofibrils. Scand J Clin Lab Invest 2007; 67: 179-190
22. Tizon B, Ribe EM, Mi W, Troy CM, Levy E. Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis 2010; 19: 885-894
23. Lenarcic B, Krasovec M, Ritonja A, Olafsson I, Turk V. Inactivation of human cystatin C and kininogen by human cathepsin D. FEBS Lett 1991; 280: 211-215
24. Tsuchiya K, Kohda Y, Yoshida M, Zhao L, Ueno T, Yamashita J, Yoshioka T, Kominami E, Yamashima T. Postictal blockade of ischemic hippocampal neuronal death in primates using selective cathepsin inhibitors. Exp Neurol 1999; 155: 187-194
25. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Gan L. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 2008; 60: 247-257
26. Finckh U, von der Kammer H, Velden J, Michel T, Andresen B, Deng A, Zhang J, Müller-Thomsen T, Zuchowski K, Menzer G, Mann U, Papassotiropoulos A, Heun R, Zurdel J, Holst F, Benussi L, Stoppe G, Reiss J, Miserez AR, Staehelin HB, Rebeck GW, Hyman BT, Binetti G, Hock C, Growdon JH, Nitsch RM. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol 2000; 57: 1579-1583
27. Cathcart HM, Huang R, Lanham IS, Corder EH, Poduslo SE. Cystatin C as a risk factor for Alzheimer disease. Neurology 2005; 64: 755-757
28. Beyer K, Lao JI, Gómez M, Riutort N, Latorre P, Mate JL, Ariza A. Alzheimer's disease and the cystatin C gene polymorphism: an association study. Neurosci Lett 2001; 315: 17-20
29. Crawford FC, Freeman MJ, Schinka JA, Abdullah LI, Gold M, Hartman R, Krivian K, Morris MD, Richards D, Duara R, Anand R, Mullan MJ. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 2000; 55: 763-768
30. Maetzler W, Schmid B, Synofzik M, Schulte C, Riester K, Huber H, Brockmann K, Gasser T, Berg D, Melms A. The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 2010; 19: 937-942
31. Yamamoto-Watanabe Y, Watanabe M, Jackson M, Akimoto H, Sugimoto K, Yasujima M, Wakasaya Y, Matsubara E, Kawarabayashi T, Harigaya Y, Lyndon AR, Shoji M. Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. Brain Res 2010; 1361: 140-145
32. Trojanowski JQ, Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007; 33: 615-620
33. Love S, Louis DN, Ellison DW. Greenfield's Neuropathology, 8th edn, London: Edward Arnold (Publishers) LTD, 2008
34. Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 2005; 20 (Suppl. 12): S29-36
35. Zurdel J, Finckh U, Menzer G, Nitsch RM, Richard G. CST3 genotype associated with exudative age related macular degeneration. Br J Ophthalmol 2002; 86: 214-219
36. Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, Hauw JJ, Seilhean D, Smith C, Walker R, Al-Sarraj S, Troakes C, Palkovits M, Kasztner M, Huitinga I, Arzberger T, Dexter DT, Kretzschmar H, Reynolds R. Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol 2010; 69: 70-81
37. Barrachina M, Castaño E, Ferrer I. TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem Int 2006; 49: 276-284
38. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108
39. T difference' formula. J Mol Med 2006; 84: 901-910
40. Beyer K, Domingo-Sàbat M, Santos C, Tolosa E, Ferrer I, Ariza A. The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain 2010; 133 (Pt 12): 3724-3733
41. Benussi L, Ghidoni R, Steinhoff T, Alberici A, Villa A, Mazzoli F, Nicosia F, Barbiero L, Broglio L, Feudatari E, Signorini S, Finckh U, Nitsch RM, Binetti G. Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol Dis 2003; 13: 15-21
42. Paraoan L, Ratnayaka A, Spiller DG, Hiscott P, White MR, Grierson I. Unexpected intracellular localization of the AMD-associated cystatin C variant. Traffic 2004; 5: 884-895
43. Noto D, Cefalu' AB, Barbagallo CM, Pace A, Rizzo M, Marino G, Caldarella R, Castello A, Pernice V, Notarbartolo A, Averna MR. Cystatin C levels are decreased in acute myocardial infarction: effect of cystatin C G73A gene polymorphism on plasma levels. Int J Cardiol 2005; 101: 213-217
44. Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol 2006; 16: 60-70
45. Yamashima T, Kohda Y, Tsuchiya K, Ueno T, Yamashita J, Yoshioka T, Kominami E. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis. Eur J Neurosci 1998; 10: 1723-1733
46. Wang C, Sun B, Zhou Y, Grubb A, Gan L. Cathepsin B degrades amyloid-β in mice expressing wild-type human amyloid precursor protein. J Biol Chem 2012; 287: 39834-39841
47. Gauthier S, Kaur G, Mi W, Tizon B, Levy E. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed) 2011; 3: 541-554
48. Abrahamson M, Buttle DJ, Mason RW, Hansson H, Grubb A, Lilja H, Ohlsson K. Regulation of cystatin C activity by serine proteinases. Biomed Biochim Acta 1991; 50: 587-593